Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCgp100 rollover study in advanced melanoma
NCT02889861Phase 2Terminated
- Sponsor
- Immunocore
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of tebentafusp in Malignant Melanoma (MM), sponsored by Immunocore. Started Jan 2017; status: terminated.
02
Drugs
tebentafusp
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02889861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889861.